Open AccessMiR‐423‐5p aggravates lung adenocarcinoma via targeting CADM1
Author(s) -
Huang Yuzhen,
Feng Ganzhu
Publication year - 2021
Publication title -
thoracic cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.823
H-Index - 28
eISSN - 1759-7714
pISSN - 1759-7706
DOI - 10.1111/1759-7714.13745
Subject(s) - downregulation and upregulation , cancer research , microrna , cell growth , cell , metastasis , western blot , adenocarcinoma , cell culture , cell migration , medicine , biology , microbiology and biotechnology , cancer , gene , genetics
Background At present, microRNAs and its downstream genes have been regarded as influential indicators in various malignancies. Therefore, the aim of this study was to explore the relationship and molecular mechanism of the miR‐423‐5p and its downstream gene CADM1 in the LUAD. Methods The pcDNA‐CADM1 was used to construct the CADM1 overexpressed cell model. The cell proliferation was determined by CCK‐8 and EdU assays and the cell metastasis was performed by wound scratch and transwell chamber assays. The relationship between miR‐423‐5p and CADM1 were determined by bioinformatics, luciferase reporter and western blot assays. Results The results revealed that the CADM1 was downregulated in LUAD tissues and cell lines. CADM1 overexpression markedly repressed the cell proliferation, migration and invasion. Moreover, the results of bioinformatics, luciferase reporter and WB assays showed that CADM1 was a target gene of miR‐423‐5p and the miR‐423‐5p expression was negatively associated with CADM1 in LUAD cell lines. Finally, rescue experiments revealed that downregulation of CADM1 could antagonize the functions of miR‐423‐5p inhibitor on cell proliferation and metastasis. These results indicated that miR‐423‐5p aggravated lung adenocarcinoma via downregulation of CADM1 expression. Conclusions Downregulation of CADM1 could antagonize the functions of miR‐423‐5p inhibitor on cell proliferation and metastasis. miR‐423‐5p aggravated lung adenocarcinoma via downregulation of CADM1 expression.